| Stem Cell Processing System |
STEM CELL PROCESSING SYSTEM
MIRACELL SMART M-CELL
Miracell, a pioneering stem cell technology firm, has achieved a significant milestone with the US Food and Drug Administration (FDA) clearance for its advanced integrated cell-processing system. This pivotal approval propels Miracell’s strategic expansion within the burgeoning global regenerative medicine market.
The comprehensive system, which received FDA approval in April, includes the innovative Smart M-Cell cell concentration device, alongside the specialized BSC blood kit and the BmSC bone marrow kit.
This prestigious FDA clearance underscores Smart M-Cell’s technological excellence, having demonstrated equivalence to “SmartPReP,” a globally recognized standard device developed by the Immune Disease Institute at Harvard Medical School. This achievement solidifies Miracell’s international reputation for sophisticated technology and superior cell extraction quality.
Stem cells offer broad therapeutic potential across various clinical fields, including the treatment of knee osteoarthritis, skin regeneration, and advanced anti-aging therapies. Autologous stem cell therapy, in particular, leverages cells extracted directly from the patient’s own blood, ensuring a high safety profile by eliminating risks of immune rejection or cell mutation.
Miracell has dedicated efforts to standardize the entire cell extraction process, encompassing collection, separation, concentration, recovery, and injection. The recent FDA clearance validates this commitment by approving the cell extraction equipment and its designated kit as a singular, integrated system, guaranteeing the collection of consistently high-quality cells.
Unlike conventional centrifuges, the Smart M-Cell is meticulously engineered to efficiently separate and concentrate a wide array of effective cells, including crucial stem cells, from both blood and bone marrow. By minimizing physical impact on the cells, it excels at obtaining a highly concentrated “total cell” yield while meticulously preserving their natural, inherent functions.
The Smart M-Cell system is currently utilized in over 700 medical institutions across Korea and is exported to approximately 40 countries, including key markets in Europe. Its global impact was recently highlighted at a European medical conference, where healthcare professionals from Spain, Serbia, and Greece presented compelling clinical cases using Smart M-Cell, with related scientific papers currently in preparation.
Domestically, researchers at Severance Hospital in Korea have published groundbreaking findings in the SCIE-level international journal Molecular Neurobiology. Their study detailed the successful treatment of severe Alzheimer’s disease using autologous stem cells extracted with the Smart M-Cell system.
The research team reported significant positive changes within the Smart M-Cell treatment group, including enhanced memory and cognitive functions, a measurable reduction in amyloid proteins—a primary biomarker of Alzheimer’s disease—and increased brain metabolism.
Looking ahead, Miracell is dedicated to expanding the therapeutic applications of its advanced stem cell treatment technologies to address a wider range of intractable diseases.
stlee0329
